$CATX

Perspective Therapeutics (CATX) has released an analyst presentation detailing its 212Pb-based theranostic pipeline and manufacturing strategy for targeted oncology. The presentation covers its VMT-α-NET program for neuroendocrine tumors and meningioma, highlighting clinical data, a regional manufacturing model for direct-to-hospital delivery, and unaudited financial estimates as of March 31, 2026. This announcement, made via an 8-K filing, outlines the company's approach to expanding market reach and optimizing production of its radiopharmaceutical products.